Omega Therapeutics Inc (OMGA) Quote

Insider Own 62.93%

epigenetics first mover with NVO deal and flagship backed..... lots of shares sold short.
See the indications listed in their presentation -- then "undisclosed" target gene partnered with Novo Nordisk for obesity -- They must have seen something they liked?

OMGA.........................https://stockcharts.com/h-sc/ui?s=OMGA&p=W&b=5&g=0&id=p86431144783

OMGA under $2

OMGA new 52 week low

OMGA new 52=week low

OMGA under $2

OMGA under $2

OMGA under $2

Interesting this might take off yet

Nobody wants any of this?
Huge deal with NVO, likely one of MANY applicants.... Flagship backed.... First in epigenetics.... So many indications, like fish in a barrel.

the bottom started bottoming

monster mega omega pop coming when people start discussing epigenetics/they unveil more data. Like 1000 indications, like shooting fish in a barrel.... more like when instead of I.
NVO wanted the foot in the door. Many more will eye it.

30% discount to level before the NVO deal was announced.
Is Flagship name. First in epigenetics............ Entire market is apathic?

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers May 08 2024 - 7:00AM

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.
“These exciting new data underscore the versatile capabilities and power of our OMEGA platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. “We have demonstrated preclinically that we can prospectively engineer epigenomic controllers to predictably and durably upregulate gene expression across a diverse range of gene types, including turning on inactivated genes, augmenting the expression of genes with low baseline expression levels, and leveraging existing genomic regulatory processes to boost expression. These capabilities unlock a wide spectrum of possibilities to apply precision epigenomic control as a novel therapeutic modality to meaningfully address key drivers of many diseases.”

OMGA under $3

It wouldn't take much to move this a good PR would do it

Omega Therapeutics: Biotech Stock with Big Upside - Read here

Omega Therapeutics (OMGA) presents a compelling investment opportunity due to its pioneering approach to medicine with programmable epigenomic-controller mRNA medicines. The company's unique Next-Gen mRNA Platform addresses the limitations of other mRNA therapies, promising fewer side effects and the ability to target previously undruggable diseases. A recent collaboration with Novo Nordisk, a pharma giant, to develop an obesity drug using Omega's platform speaks volumes about the company's technology potential and opens doors for future deals. Analysts at Wedbush and H.C. Wainwright share the optimism, with $12.00 price targets and buy ratings, but the potential is considered much bigger. Compared to established mRNA players, Omega trades at a significantly lower price, offering tremendous potential for future growth. The company has a diverse pipeline of promising candidates across various disease areas, and it is listed on the NASDAQ-GS, a market reserved for established and respected companies. Additionally, Omega is backed by Flagship Pioneering, the venture capital firm that propelled Moderna to success, signaling confidence in Omega's potential to disrupt the healthcare landscape. The company's digital and AI-based computational engine enables rapid design and development of therapeutic candidates, accelerating discovery and preclinical development. Omega's versatile platform could tackle not just fatty liver, but a variety of diseases. Despite a recent dip in share price, astute investors see this as a buying opportunity, with potential for a rapid climb past $10 and long-term prospects extending far beyond a $60 share price. Omega Therapeutics has the potential for significant growth, similar to other mRNA companies of the past. The company's innovative approach to developing a new class of programmable epigenomic mRNA medicines has garnered attention and excitement within the biotechnology industry. With the upcoming release of updated clinical data and the initiation of expansion cohorts, Omega Therapeutics is on the brink of potentially revolutionizing cancer treatment and solidifying its position as a leader in precision epigenomic control. The company's groundbreaking approach, promising data, and industry partnerships paint a strong picture, attracting substantial and ongoing investment. Omega's future looks bright, and it is considered one of the companies that is setting up for significant gains in 2024, fueled by multibillion-dollar deals, upbeat clinical results, and cutting-edge medical advances like CRISPR gene-editing hitting prime-time and programmable epigenomic-controllers being a safer option. Therefore, Omega Therapeutics (OMGA) represents an attractive investment opportunity with the potential for significant growth and a unique position in the burgeoning field of programmable epigenomic-controller mRNA medicines.

Omega Therapeutics is a leading company in the field of programmable epigenomic-controller mRNA medicine for several compelling reasons:

A Digital and AI-Based Computational Engine:

Fueled Omega's understanding of epigenetic regulation, the OMEGA platform prospectively engineers epigenomic controllers by leveraging deep expertise in machine learning and artificial intelligence (AI). Omega's modular and AI-driven approach enables rapid design and development of therapeutic candidates and the ability to accelerate discovery and preclinical development to support submission of Investigational New Drug (IND) applications within as little as 24-36 months from program inception. The speed and precision with which Omega can advance candidates into clinical studies is immensely promising for future drug development efforts and is only possible through the deterministic and computationally-guided nature of Omega's technology, coupled with Omega's pioneering vision.
Customized Delivery:
Omega's initial programs utilize lipid-nanoparticles (LNPs) to deliver our epigenomic controllers to target tissues within the body. LNPs have been established as a safe, effective and re-dosable delivery method. Looking ahead, our OMEGA platform is delivery-agnostic and can take advantage of both existing and emerging modalities tailored to the characteristics of a specific disease. Omega has deep internal expertise in formulation and delivery and are advancing in-house delivery technology development activities. In parallel, we are exploring potential external collaborations to accelerate the clinical development of our epigenomic controllers, with the goal of bringing innovative new therapies to patients sooner.

Strategic Partnerships and Industry Recognition: 
Omega has collaborations with pharmaceutical giants like Novo Nordisk for obesity management, highlighting their potential to translate research into commercially viable therapeutics.
Strong Intellectual Property Portfolio:
While it's difficult to definitively declare a single company holds the most patents in programmable epigenomic-controller mRNA medicine, given the evolving landscape and patent applications still in process, two companies stand out prominently:
Omega Therapeutics: This clinical-stage biopharma company is considered a pioneer in the field, actively developing its OMEGA platform for designing precisely targeted Epigenomic Controllers. Their website mentions a comprehensive intellectual property portfolio with "multiple issued patents and numerous pending applications covering all aspects of the OMEGA platform, including epigenomic controller design, manufacturing, and delivery.
Editas Medicine: Another leading player in gene editing technologies, Editas focuses primarily on CRISPR-based therapeutics. However, they also hold patents related to epigenetic modifications and mRNA delivery systems, which could potentially be applied to programmable epigenomic control. Their patent portfolio includes granted patents and additional filings encompassing relevant aspects of this technology.
Another player to consider:
Alnylam Pharmaceuticals: This company specializes in RNA interference (RNAi) therapeutics, which share some conceptual similarities with epigenomic control. Their extensive patent portfolio in RNA-based medicines might encompass relevant inventions applicable to programmable mRNA approaches.
Ultimately, determining the company with the absolute most patents in this specific field requires a dedicated patent search and analysis considering granted patents, pending applications, and patent scope interpretations. However, Omega Therapeutics and Editas Medicine are unquestionably at the forefront of programmable epigenomic-controller mRNA medicine development and boast comprehensive patent portfolios in this emerging area.
Remember, the patent landscape is constantly evolving, so staying updated on patent filings and granted inventions in this field remains crucial for tracking the potential leaders.

Or not

No PR today

“The Company plans to present a corporate update on January 8, 2024 at the 2024 J.P. Morgan Healthcare Conference. A copy of the presentation that will be used is furnished as Exhibit 99.2 to this Current Report on Form 8-K”

Not sure there will be another PR.

What's good news this could become $8

Jan 8th next PR according to 8K

Thanks for the laugh. I was so upset, that I didn't even notice the price, until you brought it up. 🫣

Investment Philosophy: I can't miss what I never had, BUT, I can really miss what I used to have.

Whatever helps you sleep at night.

lol, That money has flipped over so many times since that day 2 months ago. Prrreeetttty sure I'm ahead. 😜
Dead money becomes a loss as Opportunity Cost are figured in.

Whoops

GREAT Video recap on OMGA

Bought in @ $1.84. Today was a big surprise but it does have a $12 price target.
This puppy has a ways to go.

Omega Therapeutics Stock Surges 99% Following Pact with Novo Nordisk to Treat obesity
Published: Jan. 4, 2024 at 7:06 a.m. ET
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
January 04, 2024 05:59 ET
| Source: Novo Nordisk A/S
Share






Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management
Cellarity collaboration will build upon initial work and engage the company’s platform to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH)
First two research programmes signed under existing partnership between Novo Nordisk and Flagship Pioneering
Novo Nordisk will reimburse R&D costs and each company and Flagship’s Pioneering Medicines are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties
Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc.
https://www.globenewswire.com/news-release/2024/01/04/2803788/0/en/Novo-Nordisk-enters-into-research-collaborations-with-Omega-Therapeutics-and-Cellarity-on-novel-treatment-approaches-for-cardiometabolic-diseases.html

Omega Therapeutics Stock Surges 99% Following Pact with Novo Nordisk to Treat obesity
Published: Jan. 4, 2024 at 7:06 a.m. ET
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
January 04, 2024 05:59 ET
| Source: Novo Nordisk A/S
Share






Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management
Cellarity collaboration will build upon initial work and engage the company’s platform to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH)
First two research programmes signed under existing partnership between Novo Nordisk and Flagship Pioneering
Novo Nordisk will reimburse R&D costs and each company and Flagship’s Pioneering Medicines are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties
Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc.
https://www.globenewswire.com/news-release/2024/01/04/2803788/0/en/Novo-Nordisk-enters-into-research-collaborations-with-Omega-Therapeutics-and-Cellarity-on-novel-treatment-approaches-for-cardiometabolic-diseases.html

Flagship's Pioneering Medicines will be eligible to receive up to $532 million in upfront and milestone payments, along with tiered royalties. MASH is a chronic liver disease with high unmet patient need for which there is currently no treatment. Omega's stock soared 25% premarket.

What leaked?

Big drop coming 3.2.1.

https://ir.omegatherapeutics.com/news-releases/news-release-details/omega-therapeutics-participate-jefferies-london-healthcare-0

OMGA under $2

Your welcome everyone. lol

Out now that I got back even. Don't see any catalyst any time soon.

Nice move back up today.

https://www.nasdaq.com/market-activity/stocks/omga

Agreed. Almost sold on the news yesterday, just from fatigue, but held. Of course, I didn't expect for that .30 drop.
Will probably to continue to hold and add along the way.
That presentation they gave yesterday in Berlin, might just bear some fruit.
So much of their work is in the early stage time frame, that I wonder about a buyout of the technology.
I'll look into their history in that regards.

Would like to have a crystal ball as to the time frame on this puppy

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
October 31 2023 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data showcasing simultaneous and coordinated pre-transcriptional control of multiple genes co-located in an insulated genomic domain (IGD) by a single epigenomic controller (EC) at the 11th International mRNA Health Conference taking place in Berlin, Germany, October 31 – November 2, 2023.
“These new preclinical data show that, through deep understanding of disease biology and genomic architecture, our OMEGA platform is able to design a programmable mRNA candidate capable of multiplexing to pre-transcriptionally control the expression of multiple genes in preclinical models,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. “By targeting a genomic locus containing a cluster of cytokine genes, we can precisely modulate immune activity to elicit a meaningful anti-inflammatory response. The potential applications of this strategy extend beyond any single disease and highlight the broad potential of precision epigenomic control.”

Details for the poster presentation:
Title: Design and Characterization of a Programmable Epigenomic Controller Demonstrating
Multiplexed Targeting of the CXCL1-8 Gene Cluster for Treatment of Inflammatory Disorders
Poster #: 79
Session information: Flash Poster Talks / New Company Introductions Session
Date and Time: Tuesday, October 31, 2023, from 4:00 pm to 5:00 pm CET

Key Findings:

Treatment of human lung fibroblasts with CXCL1-8-targeting ECs correlated with corresponding decrease in gene expression of multiple CXCL chemokines
EC-induced changes in the epigenetic profiles of the CXCL1-8 genes were associated with decreased binding of NF-kB
Human lung fibroblasts treated with a single CXCL-EC engineered to modulate the epigenetic profiles of the CXCL1-8 gene cluster showed downregulation of both mRNA and protein levels of CXCL1, 2 and 8
Cells treated with a CXCL-EC showed decreased ability to support neutrophil migration in vitro
In a mouse model of lung inflammation, single administration of a mouse surrogate CXCL-EC resulted in decreased recruitment of neutrophils and B and T cells into bronchoalveolar fluid
The poster will be available on the Omega website at https://omegatherapeutics.com/science/publications at the same time as the presentation.

About Omega Therapeutics

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables controlled epigenomic modulation of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visit omegatherapeutics.com, or follow us on X (formerly Twitter) and LinkedIn.

OMGA new 52 week low

Mirrow trade at 16:00. 15,7785 X 2 @ 1.37

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

https://www.nasdaq.com/market-activity/institutional-portfolio/flagship-pioneering-inc-745144

OMGA's Largest Inst. Holder

https://www.nasdaq.com/market-activity/stocks/omga/institutional-holdings

OMGA: https://www.nasdaq.com/articles/omega-therapeutics-omga-price-target-increased-by-10.98-to-13.26

Confirmation of Moderna Founder link.